陇神戎发公告，公司于2026年2月5日取得由甘肃省药品监督管理局核发的《医疗器械生产许可证》，许 可证编号为甘药监械生产许20260001号。本次取得《医疗器械生产许可证》标志着公司血液透析浓缩液 （干粉）产品具备生产和上市销售的资质。 ...

证券代码：300534 证券简称：陇神戎发 公告编号：2026-003 甘肃陇神戎发药业股份有限公司 关于取得《医疗器械生产许可证》的公告 统一社会信用代码：91620000720238148G 住所：甘肃省兰州市榆中县定远镇国防路 10 号 法定代表人：康永红 企业负责人：孙波 生产地址：甘肃省兰州市榆中县定远镇国防路 10 号 生产范围：Ⅲ类：10-04-血液净化及腹膜透析器具*** 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司（以下简称"公司"）于 2026 年 2 月 5 日 取得由甘肃省药品监督管理局核发的《医疗器械生产许可证》，现将有关情况公 告如下： 一、《医疗器械生产许可证》基本信息 许可证编号：甘药监械生产许 20260001 号 企业名称：甘肃陇神戎发药业股份有限公司 尚无法预测其对公司未来业绩的具体影响，敬请广大投资者谨慎决策，注意投资 风险。 三、备查文件 1.《医疗器械生产许可证》 特此公告。 甘肃陇神戎发药业股份有限公司董事会 2026 年 2 月 5 日 许可期限：自 2026 年 2 月 4 日至 ...

（文章来源：证券日报） 证券日报网讯 2月3日，陇神戎发在互动平台回答投资者提问时表示，国家发布的《中药注册管理专门 规定》是推动中药行业高质量发展的重要举措，公司作为中药生产企业，始终严格遵循国家药品监管相 关法律法规及质量标准组织生产经营，主动对标新规持续强化质量管控，确保产品符合国家最新标准， 相关政策不会对公司经营造成不利影响。 ...

证券日报网讯1月30日，陇神戎发（300534）发布公告称，公司控股子公司甘肃药业集团三元医药有限 公司因仓库地址变更，近日获甘肃省药监局换发新《药品经营许可证》，仓库迁至兰州市榆中县定远镇 国防路10号，有效期至2028年9月18日，经营范围含中药饮片、中成药、化学药及生物制品批发。 ...

证券代码：300534 证券简称：陇神戎发 公告编号：2026-002 甘肃陇神戎发药业股份有限公司 关于控股子公司取得换发后的《药品经营许可证》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司（以下简称"公司"）控股子公司甘肃药业 集团三元医药有限公司（以下简称"三元医药"）因仓库地址变更申请更换《药 品经营许可证》，于近日收到甘肃省药品监督管理局换发后的新证。现将有关情 况公告如下： 统一社会信用代码：91620102MA73LG7052 经营地址：甘肃省兰州市城关区广武门街道秦安路 184 号第 6 层 601-603、 606、608、610 室 法定代表人（负责人）：张帆 主要负责人：刘军 质量负责人：魏萍 经营范围：中药饮片、中成药、化学药（含原料药）、生物制品，上述经营 范围含冷藏药品*** 经营方式：批发（法人） 仓库地址：甘肃省兰州市榆中县定远镇国防路 10 号 有效期至：2028 年 9 月 18 日 一、换发后的《药品经营许可证》基本信息 企业名称：甘肃药业集团三元医药有限公司 许可证编号：甘 AA93 ...

Group 1 - The company is actively seeking partnerships with both domestic and international partners to promote the internationalization of traditional Chinese medicine [2] - The company's products, including Yuanhu Zhitong Droplets and Huangqi Danggui Capsules, have been registered and are being sold in Thailand [2]

Core Viewpoint - The company is actively seeking partnerships both domestically and internationally to promote the globalization of traditional Chinese medicine [1] Group 1 - The company's products, including Yuanhu Zhitong Diban and Huangqi Danggui Capsules, have been registered and are being sold in Thailand [1]

Core Viewpoint - The company is actively seeking partnerships both domestically and internationally to promote the globalization of traditional Chinese medicine [1] Group 1: Company Developments - The company has successfully registered and is selling its products, Yuanhu Zhitong Droplets and Huangqi Danggui Capsules, in Thailand [1]

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - Sarepta's gene therapy Elevidys has shown positive results in its Phase 3 clinical trial, maintaining higher than baseline scores in the North Star Ambulatory Assessment (NSAA) after three years in patients treated at an average age of 9 [5]. - The pharmaceutical sector experienced a decline of 1.11% on January 27, 2025, underperforming the CSI 300 index by 1.08 percentage points, ranking 27th among 31 sub-industries [4]. - Among sub-industries, other biological products (+0.13%) and in vitro diagnostics (-0.07%) performed well, while vaccines (-3.55%) and offline pharmacies (-2.69%) lagged [4]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceutical Industries: Neutral [3]

Core Viewpoint - Gansu Longshen Rongfa Pharmaceutical Co., Ltd. expects a net profit of 42 million to 48.5 million yuan for the fiscal year 2025, representing a growth of 79.59% to 107.38% compared to the same period in 2024, driven by cost control and supply chain management [1] Financial Performance - The company anticipates a net profit attributable to shareholders of 42 million to 48.5 million yuan for 2025, marking a significant increase from the previous year [1] - Non-recurring gains and losses are expected to impact net profit by approximately 4 million yuan [1] Product and Market Position - The core support for the company's performance comes from its unique products, Yuanhu Zhiting Droplets and Xuanfei Zhiso Mixture, which maintain strong market positions [2] - A new production line for Xuanfei Zhiso Mixture with an annual capacity of 50 million boxes has passed GMP compliance checks and commenced production in August 2025 [2] Research and Development - The company has upgraded its research facilities and established multiple R&D platforms, including a significant acquisition of 70% of Gansu Pharmaceutical Group Technology Innovation Research Institute [3] - The company is advancing its product development, including the registration application for a new drug, and has launched several health products to enhance its product portfolio [3] International and Diversification Efforts - The company achieved important milestones in internationalization, with its health product, Huangqi Danggui Capsules, receiving official certification in Macau, facilitating market expansion [4] - New medical products, including blood dialysis powder and concentrated solutions, have received regulatory approval, paving the way for future production and sales [4]